In Portugal, multiple myeloma treatment in SNS hospitals — including CAR-T — is not paid for by the patient. Showing the cost helps explain why access takes time and why price negotiations with pharmaceutical companies matter so much.
The USA is the only country where the list price is public. Since launch, the price of both CAR-T for myeloma has gone up every year.
US list price per treatment (single dose), before discounts, converted to euros. Amounts converted to euros: €1 = 1.1052 dollars and 6.1748 reais (European Central Bank reference rates of 13/11 and 09/11/2026) and 0.8336 pounds (market rate of 05/11/2026). The original amounts are in the sources. Abecma was launched in March 2021 and Carvykti in February 2022. Source: Pulice & Schulman, Health Management, Policy and Innovation, 2026 ↗
In 2021 the independent US institute ICER calculated that Abecma needed a discount of 37% to 54% to have a fair price for its benefit. Source: Fierce Pharma ↗
- Portugal 2019: Government estimate for the first CAR-T in Portugal (lymphoma), per patient — 350.000 €. Source: Governo de Portugal ↗
- IPO Porto: Median total cost per patient treated with CAR-T at IPO Porto (study published in 2022) — 355.165 €. Source: PLOS ONE (2022) ↗
- Spain 2025–26: Carvykti bought by Madrid's public hospitals, per treatment, excluding VAT (amount deduced from the contracts) — 353.000 €. Source: Comunidad de Madrid — contratos públicos ↗
Spain: the two Madrid contracts (€2,823,999.97 in December 2025 and €1,058,999.99 in June 2026, excluding VAT) are exact multiples of €353,000, which points to that price per treatment. The contracts do not state the number of treatments.
Portugal and Carvykti. Infarmed approved public funding of Carvykti on 26 May 2025. In its assessment it concluded that the medicine was not cost-effective at the price asked and recommended a substantial price reduction; a negotiation followed. The final price is confidential, as usual. Source: Infarmed ↗
In the IPO Porto study, the medicine accounted for 97% of the total cost per patient. Source: PLOS ONE (2022) ↗
Costs left for the family. Even with treatment paid for by the SNS, there are expenses: travel, staying near the hospital in the first four weeks, the carer's time and time off work. Talk to the hospital social worker and to patient associations (APCL, APLL, Portuguese League Against Cancer) about the support available.
Figures from public sources; the actual prices paid by hospitals include confidential discounts and may be lower. Information page, not financial advice.
